February 13, 2024 — Butterfly Network, Inc., a digital health company transforming care through the power of portable, semiconductor-based ultrasound technology and intuitive software, announced today the commercial launch of its third-generation handheld point-of-care ultrasound (POCUS) system, Butterfly iQ3, which received FDA clearance last month.

February 13, 2024 — Cleerly, a digital healthcare company focused on artificial intelligence (AI)-driven heart disease diagnosis, has announced continued strong scientific evidence supporting the clinical utility of its products, detailing a study published online on Jan. 25, 2024 in the European Heart Journal Cardiovascular Imaging1.

February 12, 2024 — Sensome, a company pioneering the connected medical device revolution with the world’s smallest biological tissue sensor, announced today enrollment of the first patients into a feasibility clinical study using the Clotild Smart Guidewire in 

February 12, 2024 — BIOTRONIK, a leader in implantable medical device technology, announced today they will solely supply their proprietary DX models for new single-chamber ICD implants moving forward. The move is being made in response to overwhelming recent clinical data demonstrating superior diagnostics and decreased complication risk of DX compared to traditional high-voltage systems.1-4

February 12, 2024 — VST Bio Corp. a leader in the development of innovative biologics to treat acute and chronic cardiovascular disease, presented data from a recent large animal study performed by VST Bio and Yale University demonstrating that a single iv bolus of VST-002 led to meaningful reduction in brain damage and improved function in an advanced model of ischemic stroke.

February 12, 2023 — A team at Allina Health Minneapolis Heart Institute at Abbott Northwestern Hospital has successfully completed the first Barostim Baroreflex Activation Therapy implant in the state of Minnesota, according to an announcement from CVRx, Inc. and

February 9, 2024 — Injection of a substance to block an artery feeding the dura (protective sack around the brain) — along with surgery to remove pooled blood — reduced the risk that patients will require repeat surgery compared to surgical drainage alone.

February 9, 2024 — MIVI Neuroscience, Inc. announced the primary endpoint results of its EvaQ Trial, a prospective, multi-center, global, single arm, FDA-regulated IDE trial study to evaluate the safety and effectiveness of the MIVI Q Revascularization System for treating acute ischemic stroke.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now